{"classes":[{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation could not be calculated for a single participant.","groupId":"OG000","spread":"NA","value":"460.48"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG001","spread":"NA","value":"1024.49"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG002","spread":"NA","value":"2881.41"},{"groupId":"OG003","spread":"31.68","value":"2146.54"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG004","spread":"NA","value":"3317.10"},{"groupId":"OG005","spread":"71.29","value":"2510.55"},{"groupId":"OG006","spread":"22.42","value":"6424.74"},{"groupId":"OG007","spread":"52.85","value":"5918.90"},{"groupId":"OG008","spread":"62.01","value":"3695.32"},{"groupId":"OG009","spread":"45.28","value":"7980.72"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG010","spread":"NA","value":"5944.52"},{"groupId":"OG011","spread":"34.31","value":"8394.69"},{"groupId":"OG012","spread":"44.17","value":"5017.96"},{"groupId":"OG013","spread":"46.29","value":"13520.57"},{"groupId":"OG014","spread":"43.80","value":"13688.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"6"}],"units":"Participants"}],"title":"AUC(0-24), n=1,1,1,5,1,4,8,18,3,8,1,6,7,16, 6"},{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG000","spread":"NA","value":"466.81"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG001","spread":"NA","value":"1092.28"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG002","spread":"NA","value":"3054.11"},{"groupId":"OG003","spread":"32.55","value":"2217.32"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG004","spread":"NA","value":"3465.49"},{"groupId":"OG005","spread":"72.05","value":"2546.49"},{"groupId":"OG006","spread":"25.12","value":"6951.06"},{"groupId":"OG007","spread":"60.67","value":"6214.97"},{"groupId":"OG008","spread":"63.27","value":"3874.05"},{"groupId":"OG009","spread":"47.87","value":"8248.45"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG010","spread":"NA","value":"6032.36"},{"groupId":"OG011","spread":"29.60","value":"9734.83"},{"groupId":"OG012","spread":"44.76","value":"5114.61"},{"groupId":"OG013","spread":"52.35","value":"14635.17"},{"groupId":"OG014","spread":"35.37","value":"17021.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"5"}],"units":"Participants"}],"title":"AUC(0-inf), n=1,1,1,5,1,4,7,17,3,8,1,5,7,16,5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"6"}],"units":"Participants"}],"description":"Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population consisted of all participants in the All Treated Population for whom a PK sample was obtained and analyzed. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).","reportingStatus":"POSTED","timeFrame":"Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose","title":"Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0-24]) and AUC Extrapolated to Infinity (AUC[0-inf]) of GSK525762 Following Single Dose Administration","type":"SECONDARY","unitOfMeasure":"Hours*nanograms per milliliter"}